Andere Sprachen CombiGene AB

Aktien

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 16:59:28 03.05.2024			% 5 Tage	% 1. Jan.
3,73 ^SEK	+1,36 %		-1,06 %	+38,66 %

13.03.	CombiGenes Epilepsie-Projekt CG01 erhält in zwei neuen Ländern ein Patent	CI
21.02.	Orphazyme A/S (CPSE:ORPHA) hat eine zusätzliche unbekannte Minderheitsbeteiligung an CombiGene AB (publ) (OM:COMBI) erworben.	CI

BioStock: CombiGene's pain programme takes important steps forward	03.05.
CombiGene AB (publ) publishes annual report for 2023	26.04.
Notice of Annual General Meeting in CombiGene AB (publ)	18.04.
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	20.03.
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	13.03.
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	13.03.
BioStock: Comments from Orphazyme on the investment in CombiGene	04.03.
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21.02.
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21.02.
Year-end report January-December 2023 CombiGene AB (Publ)	16.02.
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16.02.
BioStock: CombiGene comments on the discontinued CGT2 project	02.02.
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2	01.02.
CombiGene: "We continue to believe in the epilepsy project CG01"	16.01.
CombiGene has regained the global rights to the epilepsy project CG01	13.01.
BioStock: CombiGene comments on Eurostars funding	22.12.
Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project	20.12.
New issue of CombiGenes, no 5 2023	27.11.
BioStock: CombiGene focuses on the pain project	15.11.
Interim report January – September 2023 for CombiGene AB (publ)	10.11.

Keine Ergebnisse zu dieser Suche